Breaking News
13 hours ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
PCI Pharma Services commits $1B to injectable manufacturing and device assembly, reshaping CDMO capacity for sterile fill-finish.
Pharma Now Editorial Team

Janssen's LAZCLUZE approval as a dual-modality EGFR regimen sets new operational demands for oncology manufacturers and QA teams.
Pharma Now Editorial Team

Incyte's NIKTIMVO IV biologic approval for chronic GVHD sets a regulatory and manufacturing reference point for rare disease parenteral biologics.
Pharma Now Editorial Team

Cymabay's LIVDELZI approval sets a regulatory and manufacturing reference for PPAR-delta agonists in rare liver disease submissions.
Pharma Now Editorial Team
